Kimberly Workowski, MD
Infectious Disease · Atlanta, GANPI 1588676712
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $48,820 of the $53,059 with a category attached, or 92.0%. 5 manufacturers reported payments, led by GSK at 44.3% of the total. Reporting peaked in 2024 at $15,269 and has fallen 91.2% since, to $1,350 in 2025. Among infectious disease clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 53 payments — averaging $1001.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$24K
- Janssen Scientific Affairs, LLC$13K
- Viiv Healthcare Company$8K
- Gilead$7K
- La Jolla Pharmaceutical Company$2K
Across 313 payments — averaging $6298.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$1.6M
- AbbVie$318K
- GSK$49K
- Merck$5K
What the payments were for
- Consulting fees$48,82092%
- Speaking & faculty fees$1,6083%
- Travel & lodging$1,9604%
- Food & beverage$6711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 8 | $23,517 |
| Janssen Scientific Affairs, LLC | 24 | $13,301 |
| Viiv Healthcare Company | 7 | $7,749 |
| Gilead | 12 | $6,723 |
| La Jolla Pharmaceutical Company | 2 | $1,769 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,059 in reported general payments places this provider in the 90th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 377 | $1,478,300 |
| TivicayDolutegravir Sodium | 217 | $489,547 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 100 | $375,643 |
| DescovyEmtricitabine/Tenofov Alafenam | 123 | $269,007 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 56 | $226,834 |
| PrezcobixDarunavir/Cobicistat | 83 | $193,081 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 36 | $133,039 |
| IsentressRaltegravir Potassium | 48 | $87,474 |
| CompleraEmtricita/Rilpivirine/Tenof Df | 25 | $75,181 |
| PrezistaDarunavir | 35 | $69,722 |
| OzempicSemaglutide | 51 | $52,169 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 38 | $42,739 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $38,073 |
| IntelenceEtravirine | 12 | $17,655 |
| VemlidyTenofovir Alafenamide | 12 | $17,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya, Stribild, Vemlidy | $6,723 | $2,124,402604 claims |
| Viiv Healthcare CompanyTivicay, Triumeq, Dovato | $7,749 | $903,263330 claims |
| Janssen Scientific Affairs, LLCPrezista, Intelence | $13,301 | $87,37747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Atlanta
- Zandraetta Tims-CookAtlanta$848K
- Larry AndersonAtlanta$300K
- Quintin RobinsonAtlanta$270K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
- Colleen KraftAtlanta$103K
- Walter OrensteinAtlanta$78K
- Nadine RouphaelAtlanta$66K
- Bernard BransonAtlanta$36K
- Michelle JonesAtlanta$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.